Davies M.J., D’Alessio D.A., Fradkin J., Kernan W.N., Mathieu C., Mingrone G. et al. Management of hyperglycaemia in type 2 diabetes, 2018. A consensus report by the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD). Diabetes Care. 2018;41(12):2669–2701. https://doi.org/10.2337/dci18-0033..
DOI: 10.2337/dci18-0033

Carr R.D., Solomon A. Inhibitors of dipeptidyl peptidase‐4 as therapeutic agents for individuals with type 2 diabetes: a 25‐year journey. Diabet Med. 2020;37(8):1230–1233. https://doi.org/10.1111/dme.14325..
DOI: 10.1111/dme.14325

Сидоров А.В. Клиническая фармакология ингибиторов дипептидилпептидазы 4: сравнительный обзор. Эффективная фармакотерапия. 2020;16(25):24–48. https://doi.org/10.33978/2307-3586-2020-16-25-24-48..
DOI: 10.33978/2307-3586-2020-16-25-24-48

Ahrén B. Glucose-lowering action through targeting islet dysfunction in type 2 diabetes: Focus on dipeptidyl peptidase-4 inhibition. J Diabetes Investig. 2021;12(7):1128–1135. https://doi.org/10.1111/jdi.13564..
DOI: 10.1111/jdi.13564

Kawanami D., Takashi Y., Takahashi H., Motonaga R., Tanabe M. Renoprotective Effects of DPP-4 Inhibitors. Antioxidants (Basel). 2021;10(2):246. https://doi.org/10.3390/antiox10020246..
DOI: 10.3390/antiox10020246

Narimani R., Kachuei A., Rezvanian H. Feizi A., Poorpoone M. Effect of sitagliptin on proteinuria in patients with type 2 diabetes – A renoprotective effect of sitagliptin. Res Med Sci. 2021;26:35. https://doi.org/10.4103/jrms.JRMS_78_20..
DOI: 10.4103/jrms.JRMS_78_20

Avogaro A., Fadini G.P. The pleiotropic cardiovascular effects of dipeptidyl peptidase-4 inhibitors. Br J Clin Pharmacol. 2018;84(8):1686–1695. https://doi.org/10.1111/bcp.13611..
DOI: 10.1111/bcp.13611

Packer M. Worsening Heart Failure During the Use of DPP-4 Inhibitors: Pathophysiological Mechanisms, Clinical Risks, and Potential Influence of Concomitant Antidiabetic Medications. JACC Heart Fail. 2018;6(6):445–451. https://doi.org/10.1016/j.jchf.2017.12.016..
DOI: 10.1016/j.jchf.2017.12.016

Sano M. Mechanism by which dipeptidyl peptidase-4 inhibitors increase the risk of heart failure and possible differences in heart failure risk. J Cardiol. 2019;73(1):28–32. https://doi.org/10.1016/j.jjcc.2018.07.004..
DOI: 10.1016/j.jjcc.2018.07.004

Ali A., Fuentes A., Skelton IV W.P., Wang Yu., McGorray S., Shah C. et al. A multi-center retrospective analysis of the effect of DPP4 inhibitors on progression-free survival in advanced airway and colorectal cancers. Mol Clin Oncol. 2019;10(1):118–124. https://doi.org/10.3892/mco.2018.1766..
DOI: 10.3892/mco.2018.1766

Bishnoi R., Hong Y.-R., Shah C., Ali A., Skelton 4th W.P., Huo J. et al. Dipeptidyl peptidase 4 inhibitors as novel agents in improving survival in diabetic patients with colorectal cancer and lung cancer: A Surveillance Epidemiology and Endpoint Research Medicare study. Cancer Med. 2019;8(8):3918–3927. https://doi.org/10.1002/cam4.2278..
DOI: 10.1002/cam4.2278

Kawakita E., Koya D., Kanasaki K. CD26/DPP-4: Type 2 Diabetes Drug Target with Potential Influence on Cancer Biology. Cancers (Basel). 2021;13(9):2191. https://doi.org/10.3390/cancers13092191..
DOI: 10.3390/cancers13092191

Shah C., Hong Y.-R., Bishnoi R., Ali A., Skelton 4th W.P., Dang L.H. et al. Impact of DPP4 Inhibitors in Survival of Patients With Prostate, Pancreas, and Breast Cancer. Front Oncol. 2020;10:405. https://doi.org/10.3389/fonc.2020.00405..
DOI: 10.3389/fonc.2020.00405

Angelopoulou E., Piperi C. DPP-4 inhibitors: a promising therapeutic approach against Alzheimer’s disease. Ann Transl Med. 2018;6(12):255. https://doi.org/10.21037/atm.2018.04.41..
DOI: 10.21037/atm.2018.04.41

Zhou F., Yu T., Du R., Fan G., Liu Y., Liu Z. et al. Clinical course and risk factors for mortality of adult inpatients with COVID-19 in Wuhan, China: a retrospective cohort study. Lancet. 2020;395(10229):1054–1062. https://doi.org/10.1016/S0140-6736(20)30638-3..
DOI: 10.1016/S0140-6736(20)30638-3

Holman N., Knighton P., Kar P., O’Keefe J., Curley M., Weaver A. et al. Risk factors for COVID-19-related mortality in people with type 1 and type 2 diabetes in England: a population-based cohort study. Lancet Diabetes Endocrinol. 2020;8(10):823–833. https://doi.org/10.1016/S2213-8587(20)30271-0..
DOI: 10.1016/S2213-8587(20)30271-0

Barron E., Bakhai C., Kar P., Weaver A., Bradley D., Ismail H. et al. Associations of type 1 and type 2 diabetes with COVID-19-related mortality in England: a whole-population study. Lancet Diabetes Endocrinol. 2020;8(10):813–822. https://doi.org/10.1016/S2213-8587(20)30272-2..
DOI: 10.1016/S2213-8587(20)30272-2

Mantovani A., Byrne C.D., Zheng M.-H., Targher G. Diabetes as a risk factor for greater COVID-19 severity and in-hospital death: a meta-analysis of observational studies. Nutr Metab Cardiovasc Dis. 2020;30(8):1236–1248. https://doi.org/10.1016/j.numecd.2020.05.014..
DOI: 10.1016/j.numecd.2020.05.014

Rubenfeld G.D., Caldwell E., Peabody E., Weaver J., Martin D.P., Neff M. et al. Incidence and outcomes of acute lung injury. N Engl J Med. 2005;353(16):1685–1693. https://doi.org/10.1056/NEJMoa050333..
DOI: 10.1056/NEJMoa050333

Reinhold D., Bank U., Täger M., Ansorge S., Wrenger S., Thielitz A. et al. DP IV/CD26, APN/CD13 and related enzymes as regulators of T cell immunity: implications for experimental encephalomyelitis and multiple sclerosis. Front Biosci. 2008;13:2356–2363. https://doi.org/10.2741/2849..
DOI: 10.2741/2849

Lontchi-Yimagou E., Sobngwi E., Matsha T.E., Kengne A.P. Diabetes mellitus and inflammation. Curr Diab Rep. 2013;13(3):435–444. https://doi.org/10.1007/s11892-013-0375y..
DOI: 10.1007/s11892-013-0375y

Katsiki N., Ferrannini E. Anti-inflammatory properties of antidiabetic drugs: A “promised land” in the COVID-19 era? J Diabetes Complications. 2020;34(12):107723. https://doi.org/10.1016/j.jdiacomp.2020.107723..
DOI: 10.1016/j.jdiacomp.2020.107723

Yazbeck R., Jaenisch S.E., Abbott C.A. Dipeptidyl peptidase 4 inhibitors: Applications in innate immunity? Biochem Pharmacol. 2021;188:114517. https://doi.org/10.1016/j.bcp.2021.114517..
DOI: 10.1016/j.bcp.2021.114517

Shao S., Xu Q., Yu X., Pan R., Chen Y. Dipeptidyl peptidase 4 inhibitors and their potential immune modulatory functions. Pharmacol Ther. 2020;209:107503. https://doi.org/10.1016/j.pharmthera.2020.107503..
DOI: 10.1016/j.pharmthera.2020.107503

Nargis T., Chakrabarti P. Significance of circulatory DPP4 activity in metabolic diseases. IUBMB Life. 2018;70(2):112–119. https://doi.org/10.1002/iub.1709..
DOI: 10.1002/iub.1709

Yazbeck R., Howarth G.S., Butler R.N., Geier M.S., Abbott C.A. Biochemical and histological changes in the small intestine of mice with dextran sulfate sodium colitis. J Cell Physiol. 2011;226(12):3219–3224. https://doi.org/10.1002/jcp.22682..
DOI: 10.1002/jcp.22682

Bassendine M.F., Bridge S.H., McCaughan G.W., Gorrell M.D. COVID-19 and comorbidities: A role for dipeptidyl peptidase 4 (DPP4) in disease severity? J Diabetes. 2020;12(9):649–658. https://doi.org/10.1111/1753-0407.13052..
DOI: 10.1111/1753-0407.13052

Lu G., Hu Y., Wang Q., Qi J., Gao F., Li Y. et al. Molecular basis of binding between novel human coronavirus MERS-CoV and its receptor CD26. Nature. 2013;500(7461):227–231. https://doi.org/10.1038/nature12328..
DOI: 10.1038/nature12328

Solerte S.B., D’Addio F., Trevisan R., Lovati E., Rossi A., Pastore I. et al. Sitagliptin treatment at the time of hospitalization was associated with reduced mortality in patients with type 2 diabetes and COVID-19: a multicenter, case-control, retrospective, observational study. Diabetes Care. 2020;43(13):2999–3006. https://doi.org/10.2337/dc20-1521..
DOI: 10.2337/dc20-1521

Al-Kuraishy H.M., Al-Gareeb A.I., Qusty N., Alexiou A., Batih G.E.-S. Impact of Sitagliptin in Non-Diabetic Covid-19 Patients. Curr Mol Pharmacol. 2022;15(4):683–692. https://doi.org/10.2174/1874467214666210902115650..
DOI: 10.2174/1874467214666210902115650

Alhakamy N.A., Ahmed O.A.A., Ibrahim T.S., Aldawsari H.M., Eljaaly K., Fahmy U.A. et al. Evaluation of the Antiviral Activity of SitagliptinGlatiramer Acetate Nano-Conjugates against SARS-CoV-2 Virus. Pharmaceuticals (Basel). 2021;14(3):178. https://doi.org/10.3390/ph14030178..
DOI: 10.3390/ph14030178

Al-Rabia M.W., Alhakamy N.A., Ahmed O.A.A., Eljaaly K., Alaofi A.L., Mostafa A. et al. Repurposing of Sitagliptin-Melittin Optimized Nanoformula against SARS-CoV-2: Antiviral Screening and Molecular Docking Studies. Pharmaceutics. 2021;13(3):307. https://doi.org/10.3390/pharmaceutics13030307..
DOI: 10.3390/pharmaceutics13030307

Noh Y., Oh I.-S., Jeong H.E., Filion K.B., Yu O.H.Y., Shin J.-Y. Association Between DPP-4 Inhibitors and COVID-19-Related Outcomes Among Patients With Type 2 Diabetes. Diabetes Care. 2021;44(4):e64–e66. https://doi.org/10.2337/dc20-1824..
DOI: 10.2337/dc20-1824

Yang Y., Cai Z., Zhang J. DPP-4 inhibitors may improve the mortality of coronavirus disease 2019: A meta-analysis. PLoS ONE. 2021;16(5):e0251916. https://doi.org/10.1371/journal.pone.0251916..
DOI: 10.1371/journal.pone.0251916

Rakhmat I.I., Kusmala Yu.Yu., Handayani D.R., Juliastuti H., Nawangsih E.N., Wibowo A. et al. Dipeptidyl peptidase-4 (DPP-4) inhibitor and mortality in coronavirus disease 2019 (COVID-19) – A systematic review, metaanalysis, and meta-regression. Diabetes Metab Syndr. 2021;15(3):777–782. https://doi.org/10.1016/j.dsx.2021.03.027..
DOI: 10.1016/j.dsx.2021.03.027

Sainsbury C., Wang J., Gokhale K., Acosta-Mena D., Dhalla S., Byne N. et al. Sodium-glucose co-transporter-2 inhibitors and susceptibility to COVID-19: A population-based retrospective cohort study. Diabetes Obes Metab. 2021;23(1):263–269. https://doi.org/10.1111/dom.14203..
DOI: 10.1111/dom.14203

Dalan R., Ang L.W., Tan W.Y.T., Fong S.-W., Tay W.C., Chan Y.-H. et al. The association of hypertension and diabetes pharmacotherapy with COVID-19 severity and immune signatures: an observational study. Eur Heart J Cardiovasc Pharmacother. 2021;7(3):e48–e51. https://doi.org/10.1093/ehjcvp/pvaa098..
DOI: 10.1093/ehjcvp/pvaa098

Chen Y., Yang D., Cheng B., Chen J., Peng A., Yang C. et al. Clinical Characteristics and Outcomes of Patients With Diabetes and COVID-19 in Association With Glucose-Lowering Medication. Diabetes Care. 2020;43(7):1399–1407. https://doi.org/10.2337/dc20-0660..
DOI: 10.2337/dc20-0660

Drucker D.J. Coronavirus Infections and Type 2 Diabetes-Shared Pathways with Therapeutic Implications. Endocr Rev. 2020;41(3):bnaa011. https://doi.org/10.1210/endrev/bnaa011..
DOI: 10.1210/endrev/bnaa011

Bonora B.M., Avogaro A., Fadini G.P. Disentangling conflicting evidence on DPP-4 inhibitors and outcomes of COVID-19: narrative review and meta-analysis. J Endocrinol Invest. 2021;44(7):1379–1386. https://doi.org/10.1007/s40618-021-01515-6..
DOI: 10.1007/s40618-021-01515-6

Fadini G.P., Morieri M.L., Longato E., Bonora B.M., Pinelli S., Selmin E. et al. Exposure to dipeptidyl-peptidase-4 inhibitors and COVID-19 among people with type 2 diabetes: A case-control study. Diabetes Obes Metab. 2020;22(10):1946–1950. https://doi.org/10.1111/dom.14097..
DOI: 10.1111/dom.14097

Meijer R.I., Hoekstra T., van den Oever N.C.G., Simsek S., van den Bergh J.P., Douma R.A. et al. Treatment with a DPP-4 inhibitor at time of hospital admission for COVID-19 is not associated with improved clinical outcomes: data from the COVID-PREDICT cohort study in The Netherlands. J Diabetes Metab Disord. 2021;20(2):1–6. https://doi.org/10.1007/s40200-021-00833-z.
DOI: 10.1007/s40200-021-00833-z

Pérez-Belmonte L.M., Torres-Peña J.D., López-Carmona M.D., AyalaGutiérrez M.M., Fuentes-Jiménez F., Huerta L.J. et al. Mortality and other adverse outcomes in patients with type 2 diabetes mellitus admitted for COVID-19 in association with glucose-lowering drugs: a nationwide cohort study. BMC Med. 2020;18(1):359. https://doi.org/10.1186/s12916-020-01832-2..
DOI: 10.1186/s12916-020-01832-2

Zhou J.-H., Wu B., Wang W.-X., Lei F., Cheng X., Qin J.-J. et al. No significant association between dipeptidyl peptidase-4 inhibitors and adverse outcomes of COVID-19. World J Clin Cases. 2020;8(22):5576–5588. https://doi.org/10.12998/wjcc.v8.i22.5576..
DOI: 10.12998/wjcc.v8.i22.5576

Scheen A.J. DPP-4 inhibition and COVID-19: From initial concerns to recent expectations. Diabetes Metab. 2021;47(2):101213. https://doi.org/10.1016/j.diabet.2020.11.005..
DOI: 10.1016/j.diabet.2020.11.005

Sun B., Huang S., Zhou J. Perspectives of Antidiabetic Drugs in Diabetes With Coronavirus Infections. Front Pharmacol. 2021;11:592439. https://doi.org/10.3389/fphar.2020.592439..
DOI: 10.3389/fphar.2020.592439

Bornstein S.R., Rubino F., Khunti K., Mingrone G., Hopkins D., Birkenfeld A.L. et al. Practical recommendations for the management of diabetes in patients with COVID-19. Lancet Diabetes Endocrinol. 2020;8(6):546–550. https://doi.org/10.1016/S2213-8587(20)30152-2..
DOI: 10.1016/S2213-8587(20)30152-2

Zhu L., She Z.-G., Cheng X., Qin J.-J., Zhang X.-J., Cai J. et al. Association of blood glucose control and outcomes in patients with COVID-19 and pre-existing type 2 diabetes. Cell Metab. 2020;31(6):1068–1077.e3. https://doi.org/10.1016/j.cmet.2020.04.021.
DOI: 10.1016/j.cmet.2020.04.021